Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Abraxane|DRUG: Bevacizumab|DRUG: Carboplatin
Sponsor: Duke University
Collaborators: Genentech, Inc.|Celgene Corporation